ImmuCell (NASDAQ:ICCC) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

ImmuCell Corporation (NASDAQ:ICCC)’s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.15 and traded as low as $5.80. ImmuCell shares last traded at $5.82, with a volume of 45,363 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research note on Monday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

ImmuCell Stock Performance

The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $52.67 million, a PE ratio of 22.39 and a beta of 0.20. The firm’s fifty day moving average price is $5.72 and its 200 day moving average price is $6.15.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $5.51 million for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC acquired a new position in ImmuCell Corporation (NASDAQ:ICCC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned about 0.35% of ImmuCell as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 13.47% of the company’s stock.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.